Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00322257 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes
A Phase 3 study, sponsored by Novo Nordisk A/S.
- Terminated
- Registry status
- Phase 3
- Development phase
- 596
- Enrollment target
NCT00322257 is a Phase 3 study that was terminated before completion, run by Novo Nordisk A/S. The registered enrollment target is 596 participants.
The verdict
NCT00322257, a Phase 3 study, was terminated before completion, sponsored by Novo Nordisk A/S.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 596 participants
- Enrollment target
Study Summary
This trial is conducted in the United States of America (USA) and Canada. The aim of this research is to compare the efficacy (reduction in HbA1c and blood glucose) and pulmonary safety (pulmonary function, chest x-rays) of mealtime inhaled insulin with subcutaneous insulin aspart both in combination with insulin determir in Type 1 Diabetes.
Interventions
- DRUG insulin aspart
- DRUG insulin detemir
- DRUG inhaled human insulin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 596 participants |
| Start Date | 2006-05-01 |
| Est. Completion | 2008-04-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00322257
The ClinicalTrials.gov registry entry for NCT00322257 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 596 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which insulin aspart is the first listed.
NCT00322257 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00322257 about?
NCT00322257 is a clinical study titled "Safety and Efficacy of Inhaled Insulin in Type 1 Diabetes". This trial is conducted in the United States of America (USA) and Canada. The aim of this research is to compare the efficacy (reduction in HbA1c and blood glucose) and pulmonary safety (pulmonary function, chest x-rays) of mealtime inhaled insulin with subcutaneous insulin aspart both in combinatio...
What is the current status of trial NCT00322257?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 596 participants. The study started on 2006-05-01. Estimated completion is 2008-04-02.
What interventions are being tested in trial NCT00322257?
The interventions under investigation include: insulin aspart (DRUG), insulin detemir (DRUG), inhaled human insulin (DRUG).
Who is sponsoring clinical trial NCT00322257?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.